CClinicalTrials.gg
CompletedNCT06261372Updated Feb 15, 2024

Mindfulness Meditation Combined With Progressive Muscle Relaxation Training for Uremic Sarcopenia

An interventional study of The mindfulness meditation combined with progressive muscle relaxation training . in Hemodialysis Patients With Sarcopenia, sponsored by Ningbo Medical Center Lihuili Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Ningbo Medical Center Lihuili Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2023, registered Jan 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To study the effect of mindfulness meditation combined with progressive muscle relaxation training on clinical efficacy and quality of life in maintenance hemodialysis (MHD) patients with sarcopenia. Eligible sarcopenic patients in our hospital were randomly assigned to a control group (n = 24) and an intervention group (n = 25). The control group received conventional dialysis treatment, while the intervention group received mindfulness meditation combined with progressive muscle relaxation training during the interdialysis period in addition to conventional dialysis treatment. The effect of the intervention was evaluated after 12 weeks.To observe whether the combined intervention training can improve the motor ability and quality of life of patients with sarcopenia in a short period of time.

02

Conditions studied

  • Hemodialysis Patients With Sarcopenia

Browse trials for

Keywords

  • mindfulness meditation
  • progressive muscle relaxation
  • uremic sarcopenia
  • maintenance hemodialysis
  • quality of life
03

In context

Sarcopenia

1,211 studies on the registry are indexed under Sarcopenia; 403 are open to participants now.

This study's enrollment of 49 is below the median of 60 across 776 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Ningbo Medical Center Lihuili Hospital is the lead sponsor of 15 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who met the sarcopenia criteria established by the Asian Working Group for Sarcopenia (AWGS) in 2014
  • Stable condition and generally good health status
  • Good compliance and ability to collaborate well with the physician
  • Undergoing hemodialysis three times per week for at least three months, with a KT/V ≥ 1.2
  • No significant cardiovascular or cerebrovascular complications (such as severe heart failure, severe arrhythmias, angina, and cerebrovascular diseases)
  • Patients with sarcopenia who met the clinical diagnostic criteria were selected to ensure the quality of the included patients

Exclusion criteria

Exclusion Criteria:

  • Inability to complete handgrip strength, 6-meter walk test, 10 sit-to-stand tests, and the use of bioelectrical impedance analysis (BIA) due to contraindications
  • Coexistence of mental illness or severe cognitive or communication disorders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • No intervention
    control group

    The control group received conventional dialysis treatment.

  • Other
    intervention group

    In addition to conventional treatment, mindfulness meditation combined with progressive muscle relaxation training was implemented during the interdialytic period.

    Behavioral: The mindfulness meditation combined with progressive muscle relaxation training .

Interventions

  • BehavioralThe mindfulness meditation combined with progressive muscle relaxation training .

    The first part is progressive muscle relaxation training. The second part is mindfulness meditation training.

06

What researchers measure

Primary outcomes

  1. 10 sit-to-stand test in seconds

    The 10 sit-stand test represents exercise ability, and the shorter the time, the greater the exercise ability.

    Time frame: 3 months

  2. Grip strength in kilograms

    Grip strength represents exercise ability, and the larger it is, the more exercise ability it is.Its minimum value is zero, and its maximum value is unlimited.

    Time frame: 3 months

  3. 6-meter walk test in metre per second

    6-meter walk test represents exercise ability, and the larger it is, the more exercise ability it is.Its minimum value is zero metre per second, and its maximum value is unlimited.

    Time frame: 3 months

  4. KDQOLTM(Kidney Disease Quality of Life short Form) score

    The KDQOLTM score is between 0 and 100, and the higher the score, the better the health

    Time frame: 3 months

  5. interleukin-6 (IL-6)

    Interleukin 6 represents an inflammatory marker, and its concentration is 20pg/ml or less.

    Time frame: 3 months

  6. high-sensitivity C-reactive protein (hsCRP)

    hsCRP represents an inflammatory marker, and its concentration ranges from 0.0 to 10mg/L.

    Time frame: 3 months

  7. albumin(ALB)

    Albumin represents a nutritional indicator, and its concentration ranges from 40 to 55g/L.

    Time frame: 3 months

  8. prealbumin (PA)

    Prealbumin represents a nutritional indicator, and its concentration ranges from 0.20 to 0.43g/l.

    Time frame: 3 months

07

Study locations

1 site
  • Li Huili Hospital, Ningbo Medical Center
    Ningbo, Zhejiang 315046, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06261372
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Responsible party
Sponsor
First posted
Feb 15, 2024
Start date
Aug 15, 2023
Primary completion
Nov 15, 2023
Completion
Nov 15, 2023
Last update
Feb 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion